SCHEMBL29367143

SCHEMBL29367143

O=C(c1ccc([18F])cc1)C1CCN(CCn2c(=O)c3ccccc3n(CC[18F])c2=O)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 6/20 0.66
CYP3A4 P08684 4/20 0.66
HPGD P15428 3/20 0.66
HTR2C P28335 3/20 0.66
CYP1A2 P05177 3/20 0.66
HTR1A P08908 2/20 0.66
CYP2C9 P11712 2/20 0.66
DRD2 P14416 2/20 0.66
ALDH1A1 P00352 2/20 0.66
CYP2C19 P33261 2/20 0.66
LMNA P02545 2/20 0.66
HTR7 P34969 2/20 0.66
HTR6 P50406 2/20 0.66
MEN1 O00255 1/20 0.66
MAPT P10636 1/20 0.66
ADRA2B P18089 1/20 0.66
ADRA2C P18825 1/20 0.66
DRD1 P21728 1/20 0.66
DRD4 P21917 1/20 0.66
HTR1D P28221 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3890962 1.00 HTR2A (0.66) HTR2ACYP3A4HPGDHTR2CCYP1A2
SCHEMBL11014375 0.87 HTR2A (0.63) HTR2ACYP3A4HPGDHTR2CCYP1A2
Hydrochloric Acid SCHEMBL6402659 0.87 HTR2A (0.58) HTR2ACYP3A4HPGDHTR2CCYP1A2
SCHEMBL11495934 0.86 HTR2A (0.62) HTR2ACYP3A4HPGDHTR2CCYP1A2
SCHEMBL2946959 0.83 CYP2D6 (0.59) HTR2ACYP3A4HPGDHTR2CCYP1A2
Hydrochloric Acid SCHEMBL8025211 0.82 HTR2A (0.60) HTR2ACYP3A4HPGDHTR2CCYP1A2
Hydrochloric Acid SCHEMBL8021166 0.82 HTR2A (0.61) HTR2ACYP3A4HPGDHTR2CCYP1A2
SCHEMBL464537 0.82 HTR2A (0.72) HTR2ACYP3A4HPGDHTR2CCYP1A2
Hydrochloric Acid SCHEMBL8019007 0.80 KMT2A (0.57) HTR2ACYP3A4HPGDHTR2CCYP1A2
Ketanserin SCHEMBL34294 0.80 HTR2A (1.00) HTR2ACYP3A4HPGDHTR2CCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206776-A1 ENZYME-INSTRUCTED SELF-ASSEMBLY OF PEPTIDES CONTAINING N-TERMINAL PHOSPHO-AROMATIC CAPPING MOTIF, AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-06-26 US claimed
CN-117767947-A Real-time design and frequency response calibration method and device for DBI-DAC system 深圳华中科技大学研究院 2024-03-26 CN claimed
WO-2023039174-A2 ENZYME-INSTRUCTED SELF-ASSEMBLY OF PEPTIDES CONTAINING N-TERMINAL PHOSPHO-AROMATIC CAPPING MOTIF, AND USES THEREOF BANDEIS UNIVERSITY (US) 2023-03-16 WO claimed
US-20250206776-A1 ENZYME-INSTRUCTED SELF-ASSEMBLY OF PEPTIDES CONTAINING N-TERMINAL PHOSPHO-AROMATIC CAPPING MOTIF, AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2025-06-26 US disclosed
US-20250200802-A1 Multi-Stage Object Pose Estimation SIEMENS AKTIENGESELLSCHAFT (DE) 2025-06-19 US disclosed
US-12335074-B2 Multi-tap decision feed-forward equalizer with precursor and postcursor taps TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2025-06-17 US disclosed
US-12176912-B2 Electronic devices converting input signals to digital value and operating methods of electronic devices SAMSUNG ELECTRONICS CO., LTD. (KR) 2024-12-24 US disclosed
US-20240372759-A1 SERDES RECEIVER WITH OPTIMIZED CDR PULSE SHAPING TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2024-11-07 US disclosed
US-12074737-B2 SerDes receiver with optimized CDR pulse shaping TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2024-08-27 US disclosed
US-20240223413-A1 MULTI-TAP DECISION FEED-FORWARD EQUALIZER WITH PRECURSOR AND POSTCURSOR TAPS TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2024-07-04 US disclosed
EP-4359533-A2 COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF GENES Versameb AG (CH) 2024-05-01 EP disclosed
CN-116737052-A Electronic device for converting input signal into digital value and operation method thereof 三星电子株式会社 2023-09-12 CN disclosed
WO-2023039174-A2 ENZYME-INSTRUCTED SELF-ASSEMBLY OF PEPTIDES CONTAINING N-TERMINAL PHOSPHO-AROMATIC CAPPING MOTIF, AND USES THEREOF BANDEIS UNIVERSITY (US) 2023-03-16 WO disclosed
WO-2022269356-A2 COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF GENES VERSAMEB AG (CH) 2022-12-29 WO disclosed
WO-2022258720-A1 INTERFERON-ASSOCIATED ANTIGEN BINDING PROTEINS FOR USE FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION EVOTEC INTERNATIONAL GMBH (DE) 2022-12-15 WO disclosed
US-20220360476-A1 MULTI-TAP DECISION FEED-FORWARD EQUALIZER WITH PRECURSOR AND POSTCURSOR TAPS TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2022-11-10 US disclosed
US-11398933-B2 Multi-tap decision feed-forward equalizer with precursor and postcursor taps TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2022-07-26 US disclosed
US-20220158878-A1 SERDES RECEIVER WITH OPTIMIZED CDR PULSE SHAPING TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2022-05-19 US disclosed
EP-3979988-A1 SYNTHETIC LIPIDS FOR MRNA DELIVERY TRUSTEES OF TUFTS COLLEGE (US) 2022-04-13 EP disclosed
US-11240075-B2 SerDes receiver with optimized CDR pulse shaping TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) 2022-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250206776-A1 ENZYME-INSTRUCTED SELF-ASSEMBLY OF PEPTIDES CONTAINING N-TERMINAL PHOSPHO-AROMATIC CAPPING MOTIF, AND USES THEREOF ANPEP, DNPEP, PTMS HTR2A 2303/4885CYP3A4 3631/4885HPGD 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.